Evidence map›Paper›PMID 40647442›Full record

ArticleCancers2025

The Role of ENHO in Pancreatic Adenocarcinoma: A Bioinformatics Approach.

Osama M Younis, Zeid K Al-Sharif, Ahmad E Saeed, Fares B Qubbaj, Jehad A Yasin, Tasnim Nour, Yassine Alami Idrissi, Anwaar Saeed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Osama M YounisDivision of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA.ORCID 0009-0004-1027-554X
Zeid K Al-SharifSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Ahmad E SaeedSchool of Medicine, The University of Jordan, Amman 11942, Jordan.ORCID 0009-0000-9632-6731
Fares B QubbajSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Jehad A YasinSchool of Medicine, The University of Jordan, Amman 11942, Jordan.ORCID 0000-0002-9205-2988
Tasnim NourSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Yassine Alami IdrissiDivision of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA.ORCID 0009-0000-6565-4679
Anwaar SaeedDivision of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic adenocarcinoma (PAAD) is an aggressive subtype of pancreatic cancer that is estimated to have a 5-year overall survival rate of only 13%. Most patients present with advanced disease with unpredictable outcomes. The identification of prognostic biomarkers is important to accurately stratify these patients.

methodsWe investigated the molecular and survival-related role of

resultsWe observed that

conclusionsOur results point to a protective role for

Indexed as

AdropinbioinformaticsENHOpancreatic adenocarcinoma

Identifiers

PMID40647442
PMCPMC12248484

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.